Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11045865 | 0.98 | ALDH1A1 (0.67) | ALDH1A1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL11044991 | 0.98 | ALDH1A1 (0.67) | ALDH1A1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL12085964 | 0.98 | ALDH1A1 (0.67) | ALDH1A1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13668184 | 0.91 | ALDH1A1 (0.58) | ALDH1A1CHRM2CHRM4CHRM5CHRM3 | |
| Oxirane SCHEMBL11628011 | 0.90 | ALDH1A1 (0.86) | ALDH1A1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL15503288 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL15503170 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL401560 | 0.83 | — | — | |
| SCHEMBL402955 | 0.83 | — | — | |
| SCHEMBL93565 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-9611215-B2 | Nucleophile-reactive sulfonated compounds for the (radio)labelling of (bio) molecules; precursors and conjugates thereof | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2017-04-04 | — | — | US | disclosed |
| EP-2417177-A1 | OLIGOMERIC AND POLYMERIC SEMICONDUCTORS BASED ON THIENOTHIAZOLES | Heraeus Precious Metals GmbH & Co. KG (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115623-A1 | OLIGOMERIC AND POLYMERIC SEMICONDUCTORS BASED ON THIENOTHIAZOLES | H.C.STARCK CLEVIOS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| EP-1024139-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2- 6-(HYDROXYMETHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | ALDH1A1 3125/4885CHRM2 4863/4885CHRM4 4884/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | ALDH1A1 2918/4885CHRM2 4780/4885CHRM4 4883/4885 |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | ALDH1A1 3125/4885CHRM2 4863/4885CHRM4 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.